PDS BIOTECHNOLOGY CORP

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

24 2月 2022 09:10:00 条件 Nasdaq GlobeNewswire

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

15 2月 2022 07:00:04 条件 Nasdaq GlobeNewswire

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

02 2月 2022 07:00:01 条件 Nasdaq GlobeNewswire

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

27 1月 2022 07:00:02 条件 Nasdaq GlobeNewswire

PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference

18 1月 2022 07:00:01 条件 Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

12 1月 2022 07:00:01 条件 Nasdaq GlobeNewswire

PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

10 1月 2022 06:00:01 条件 Nasdaq GlobeNewswire

PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference

05 1月 2022 07:00:02 条件 Nasdaq GlobeNewswire

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

23 12月 2021 15:00:00 条件 Nasdaq GlobeNewswire

PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

06 12月 2021 07:30:00 条件 Nasdaq GlobeNewswire